XTX Topco Ltd Has $71,000 Holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

XTX Topco Ltd decreased its position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) by 28.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 123,233 shares of the company’s stock after selling 48,230 shares during the period. XTX Topco Ltd’s holdings in Unicycive Therapeutics were worth $71,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in UNCY. Nantahala Capital Management LLC boosted its position in shares of Unicycive Therapeutics by 268.5% during the 4th quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company’s stock worth $8,253,000 after acquiring an additional 7,571,636 shares in the last quarter. Vivo Capital LLC boosted its position in shares of Unicycive Therapeutics by 123.0% during the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company’s stock worth $7,918,000 after acquiring an additional 5,500,000 shares in the last quarter. Octagon Capital Advisors LP boosted its position in shares of Unicycive Therapeutics by 16.8% during the 4th quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company’s stock worth $7,942,000 after acquiring an additional 1,441,000 shares in the last quarter. Acuta Capital Partners LLC boosted its position in shares of Unicycive Therapeutics by 16.4% during the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock worth $1,829,000 after acquiring an additional 323,801 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock worth $417,000 after acquiring an additional 122,089 shares in the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on UNCY shares. HC Wainwright upgraded shares of Unicycive Therapeutics to a “strong-buy” rating and set a $90.00 price target on the stock in a research report on Tuesday, May 27th. Guggenheim initiated coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They issued a “buy” rating and a $60.00 price objective for the company.

Unicycive Therapeutics Stock Performance

UNCY stock opened at $4.70 on Friday. The company has a fifty day moving average price of $5.22 and a 200-day moving average price of $5.69. The company has a market capitalization of $59.41 million, a P/E ratio of -1.14 and a beta of 1.88. Unicycive Therapeutics, Inc. has a 52-week low of $2.75 and a 52-week high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.18. As a group, sell-side analysts forecast that Unicycive Therapeutics, Inc. will post -0.23 earnings per share for the current fiscal year.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.